Atopix Therapeutics Limited was acquired by Chiesi Farmaceutici S.p.A. in November 2016 (see press release) and as a result the Atopix office in the UK will close on 28th June 2019.
Ongoing activites will be managed by Chiesi and all enquiries should be directed to Chiesi Farmaceutici S.p.A.
Atopix Therapeutics Limited is a clinical stage biotechnology company developing novel treatments for Th2-mediated eosinophilic asthma
Timapiprant is a new molecular entity with an excellent safety profile demonstrated in over 800 subjects
CRTH2 receptor and its role in allergy